The components of drug-linker conjugates for antibody drug conjugates (ADCs) are a cytotoxic drug that is active and a suitable linker. These conjugates can be used to create ADCs, which are highly selective and cytotoxic agents that are targeted for cancer cells after being joined to a monoclonal antibody.
The drug units in drug-linker conjugates are tubulin inhibitors and DNA damaging agents that have antitumor activity (i.e., ADC cytotoxins or payloads). Auristatins and Maytansinoids are the most widely used tubulin inhibitors, while Duocarmycins, Pyrrolobenzodiazepines, Camptothecines, and Daunorubicins/Doxorubicines are the most frequently used DNA damaging agents in ADCs. Additionally, a variety of conventional cytotoxic agents can be used in ADCs.
Cleavable and noncleavable ADC linkers are the two categories into which the majority of those currently undergoing clinical evaluation fall. Noncleavable linkers necessitate proteolytic degradation of the antibody component of the ADC in order to release the cytotoxic molecule, whereas cleavable linkers depend on cellular processes to release the toxin.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V4653 | Deruxtecan | 1599440-13-7 | Deruxtecan (DS-8201a; DS8201a; exatecan analog; DX-8951 analog), a drug-linker conjugate for antibody-drug conjugate (ADC, Patritumab deruxtecan orU3-1402), is a novel, potent toxin and linker moiety of DS-8201. |
|
V51087 | Mipsagargin (G-202) | 1245732-48-2 | thapsigargin-based PDC targeting PSMA |
|
V20208 | Doxorubicin-SMCC | 400647-59-8 | Doxorubicin-SMCC (dox-SMCC); ADR-SMCC) is a doxorubicin analog used as drug-linker conjugate for the synthesis of antibody-drug-conjugates (ADC). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
